280 related articles for article (PubMed ID: 21269507)
1. O6-Methylguanine-DNA methyltransferase protein expression by immunohistochemistry in brain and non-brain systemic tumours: systematic review and meta-analysis of correlation with methylation-specific polymerase chain reaction.
Brell M; Ibáñez J; Tortosa A
BMC Cancer; 2011 Jan; 11():35. PubMed ID: 21269507
[TBL] [Abstract][Full Text] [Related]
2. Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients.
Sartore-Bianchi A; Pietrantonio F; Amatu A; Milione M; Cassingena A; Ghezzi S; Caporale M; Berenato R; Falcomatà C; Pellegrinelli A; Bardelli A; Nichelatti M; Tosi F; De Braud F; Di Nicolantonio F; Barault L; Siena S
Eur J Cancer; 2017 Jan; 71():43-50. PubMed ID: 27997874
[TBL] [Abstract][Full Text] [Related]
3. [Detection of O6-methylguanine-DNA methyltransferase promoter methylation in chemotherapy for glioma].
Zheng CQ; Ji SP; Gong F; Li AM; Tai JL; Zhang YP
Ai Zheng; 2009 Jun; 28(6):575-80. PubMed ID: 19635193
[TBL] [Abstract][Full Text] [Related]
4. Post-transcriptional regulation of O(6)-methylguanine-DNA methyltransferase MGMT in glioblastomas.
Ramakrishnan V; Kushwaha D; Koay DC; Reddy H; Mao Y; Zhou L; Ng K; Zinn P; Carter B; Chen CC
Cancer Biomark; 2011-2012; 10(3-4):185-93. PubMed ID: 22674304
[TBL] [Abstract][Full Text] [Related]
5. Correlation between quantified promoter methylation and enzymatic activity of O6-methylguanine-DNA methyltransferase in glioblastomas.
Kishida Y; Natsume A; Toda H; Toi Y; Motomura K; Koyama H; Matsuda K; Nakayama O; Sato M; Suzuki M; Kondo Y; Wakabayashi T
Tumour Biol; 2012 Apr; 33(2):373-81. PubMed ID: 22274924
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas.
Brell M; Tortosa A; Verger E; Gil JM; Viñolas N; Villá S; Acebes JJ; Caral L; Pujol T; Ferrer I; Ribalta T; Graus F
Clin Cancer Res; 2005 Jul; 11(14):5167-74. PubMed ID: 16033832
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort.
Metellus P; Coulibaly B; Nanni I; Fina F; Eudes N; Giorgi R; Barrie M; Chinot O; Fuentes S; Dufour H; Ouafik L; Figarella-Branger D
Cancer; 2009 Oct; 115(20):4783-94. PubMed ID: 19637364
[TBL] [Abstract][Full Text] [Related]
8. Evaluation status and prognostic significance of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in pediatric high grade gliomas.
Buttarelli FR; Massimino M; Antonelli M; Lauriola L; Nozza P; Donofrio V; Arcella A; Oliva MA; Di Rocco C; Giangaspero F
Childs Nerv Syst; 2010 Aug; 26(8):1051-6. PubMed ID: 20552207
[TBL] [Abstract][Full Text] [Related]
9. Promoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a reference.
Morandi L; Franceschi E; de Biase D; Marucci G; Tosoni A; Ermani M; Pession A; Tallini G; Brandes A
BMC Cancer; 2010 Feb; 10():48. PubMed ID: 20167086
[TBL] [Abstract][Full Text] [Related]
10. Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma.
Vlassenbroeck I; Califice S; Diserens AC; Migliavacca E; Straub J; Di Stefano I; Moreau F; Hamou MF; Renard I; Delorenzi M; Flamion B; DiGuiseppi J; Bierau K; Hegi ME
J Mol Diagn; 2008 Jul; 10(4):332-7. PubMed ID: 18556773
[TBL] [Abstract][Full Text] [Related]
11. O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment.
Jha P; Suri V; Jain A; Sharma MC; Pathak P; Jha P; Srivastava A; Suri A; Gupta D; Chosdol K; Chattopadhyay P; Sarkar C
Neurosurgery; 2010 Dec; 67(6):1681-91. PubMed ID: 21107199
[TBL] [Abstract][Full Text] [Related]
12. MGMT immunohistochemical expression and promoter methylation in human glioblastoma.
Rodriguez FJ; Thibodeau SN; Jenkins RB; Schowalter KV; Caron BL; O'neill BP; James CD; Passe S; Slezak J; Giannini C
Appl Immunohistochem Mol Morphol; 2008 Jan; 16(1):59-65. PubMed ID: 18091318
[TBL] [Abstract][Full Text] [Related]
13. A methylation-specific and SYBR-green-based quantitative polymerase chain reaction technique for O6-methylguanine DNA methyltransferase promoter methylation analysis.
Hattermann K; Mehdorn HM; Mentlein R; Schultka S; Held-Feindt J
Anal Biochem; 2008 Jun; 377(1):62-71. PubMed ID: 18384736
[TBL] [Abstract][Full Text] [Related]
14. Impaired expression and promotor hypermethylation of O6-methylguanine-DNA methyltransferase in retinoblastoma tissues.
Choy KW; Pang CP; To KF; Yu CB; Ng JS; Lam DS
Invest Ophthalmol Vis Sci; 2002 May; 43(5):1344-9. PubMed ID: 11980845
[TBL] [Abstract][Full Text] [Related]
15. Promoter hypermethylation of the DNA repair gene O6-methylguanine-DNA methyltransferase is an independent predictor of shortened progression free survival in patients with low-grade diffuse astrocytomas.
Komine C; Watanabe T; Katayama Y; Yoshino A; Yokoyama T; Fukushima T
Brain Pathol; 2003 Apr; 13(2):176-84. PubMed ID: 12744471
[TBL] [Abstract][Full Text] [Related]
16. Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours.
McCormack AI; McDonald KL; Gill AJ; Clark SJ; Burt MG; Campbell KA; Braund WJ; Little NS; Cook RJ; Grossman AB; Robinson BG; Clifton-Bligh RJ
Clin Endocrinol (Oxf); 2009 Aug; 71(2):226-33. PubMed ID: 19067722
[TBL] [Abstract][Full Text] [Related]
17. DNA repair gene O6-methylguanine-DNA methyltransferase: promoter hypermethylation associated with decreased expression and G:C to A:T mutations of p53 in brain tumors.
Yin D; Xie D; Hofmann WK; Zhang W; Asotra K; Wong R; Black KL; Koeffler HP
Mol Carcinog; 2003 Jan; 36(1):23-31. PubMed ID: 12503076
[TBL] [Abstract][Full Text] [Related]
18. Exclusion of histiocytes/endothelial cells and using endothelial cells as internal reference are crucial for interpretation of MGMT immunohistochemistry in glioblastoma.
Hsu CY; Lin SC; Ho HL; Chang-Chien YC; Hsu SP; Yen YS; Chen MH; Guo WY; Ho DM
Am J Surg Pathol; 2013 Feb; 37(2):264-71. PubMed ID: 23282970
[TBL] [Abstract][Full Text] [Related]
19. Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma.
Jung TY; Jung S; Moon KS; Kim IY; Kang SS; Kim YH; Park CS; Lee KH
Oncol Rep; 2010 May; 23(5):1269-76. PubMed ID: 20372840
[TBL] [Abstract][Full Text] [Related]
20. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.
Esteller M; Garcia-Foncillas J; Andion E; Goodman SN; Hidalgo OF; Vanaclocha V; Baylin SB; Herman JG
N Engl J Med; 2000 Nov; 343(19):1350-4. PubMed ID: 11070098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]